Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityJennifer L. Leddon, Timothy P. Cripe, Francesca Jung et al.|Molecular Therapy — Oncolytics|2014Cited by 44
Abstract A74: The tumor immunologic microenvironment influences antitumor efficacy of oncolytic herpes simplex virotherapyJennifer L. Leddon, Timothy P. Cripe, Chun‐Yu Chen et al.|Cancer Research|2014Cited by 0